Stryker Corporation

New York Stock Exchange
Back to all articles
Bullish +55

Debra King Sells 826 Shares of Stryker (NYSE:SYK) Stock

AI-generated analysis

📉 Insider Debra King sold 826 shares for $277,783.80 on August 18th, reducing her stake by 11.74% while retaining over $2 million in holdings.

💰 Stryker reported Q2 earnings of $3.69 per share, beating consensus estimates of $3.49, with revenue reaching $6.59 billion against expectations of $6.58 billion.

📈 Revenue grew 9.4% year-over-year to $6.59 billion, driven by performance in orthopedics, surgical equipment, and neurotechnology segments.

🎯 The company provided FY 2026 EPS guidance between $14.95 and $15.10, closely matching the analyst consensus target of $15.02.

💵 Stryker maintains a healthy balance sheet with a debt-to-equity ratio of 0.59 and a current ratio of 2.16, supporting operational flexibility.

📊 Analysts hold mixed but generally positive views, with JPMorgan lowering its target to $350 while Citigroup reaffirms a buy rating.

💸 The company declared a quarterly dividend of $0.88 payable on October 30th, offering a yield of 1.1% to shareholders.

🏦 Institutional ownership remains high at 77.09%, with multiple funds like Gables Capital and Compass Financial adding new positions recently.

Bullish Signals
  • Stryker beat earnings expectations with $3.69 EPS versus the $3.49 consensus, demonstrating strong operational execution.
  • Revenue of $6.59 billion exceeded analyst estimates of $6.58 billion, indicating robust demand for its medical technology products.
  • The company achieved a net margin of 14.43% and a return on equity of 23.63%, reflecting efficient capital allocation.
  • Revenue grew 9.4% year-over-year, signaling continued market expansion in orthopedics and surgical equipment sectors.
  • Institutional investors are accumulating shares, with Gables Capital, Kilter Group, and others adding new stakes totaling over $100,000.
Risk Factors
  • Insider Debra King reduced her shareholding by 11.74% through a sale of 826 shares, though she retains a significant position.
  • JPMorgan Chase lowered its price target from $400 to $350, suggesting potential near-term valuation concerns despite the overweight rating.
Full Analysis
Stryker Corporation (NYSE:SYK) saw insider Debra King sell 826 shares on August 18th at an average price of $336.30, reducing her position by 11.74% while retaining 6,210 shares valued at approximately $2.09 million. The transaction was disclosed to the SEC and occurred as the stock traded near its 50-day moving average, reflecting ongoing institutional and insider monitoring of the medical technology giant's equity. Financially, Stryker reported strong quarterly results with earnings per share of $3.69, beating analyst estimates of $3.49, and revenue of $6.59 billion, slightly exceeding expectations of $6.58 billion. The company achieved a net margin of 14.43% and returned equity of 23.63%, with revenue growing 9.4% year-over-year. Management has provided fiscal 2026 guidance ranging from $14.95 to $15.10 per share, aligning closely with analyst consensus projections. Analyst sentiment remains mixed but generally positive, with JPMorgan lowering its target price to $350 while maintaining an overweight rating, and Citigroup reaffirming a buy stance. The company maintains a robust balance sheet with a debt-to-equity ratio of 0.59 and pays a quarterly dividend of $0.88, yielding 1.1%. Institutional ownership stands at 77.09%, with several funds acquiring new stakes in the second and fourth quarters. Stryker operates globally across orthopedics, surgical equipment, neurotechnology, and patient-handling solutions for hospitals and healthcare facilities. Despite the insider sale, the company's fundamental metrics, including a market cap of $127.33 billion and a PEG ratio of 2.16, suggest continued investor interest in its growth trajectory within the medical device sector.